| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Aerovate Therapeutics, Inc. | CHIEF COMMERCIAL OFFICER | Stock Option (Right to Buy) | 66,586 | $898,245 | $13.49 | 22 Jan 2024 | Direct |
| Aerovate Therapeutics, Inc. | CHIEF COMMERCIAL OFFICER | Common Stock | 1,291 | $25,175 | $19.50 | 22 Jan 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| JBIO | Aerovate Therapeutics, Inc. | 22 Jan 2024 | 1 | $0 | 4 | CHIEF COMMERCIAL OFFICER | 24 Jan 2024, 18:00 |
| JBIO | Aerovate Therapeutics, Inc. | 07 Mar 2023 | 0 | $0 | 3 | Chief Commercial Officer | 08 Mar 2023, 17:01 |